Cargando…

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer (NSCLC) cells. Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. GZ17-6.02 did not interact with any EGFR inhibitor to k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Booth, Laurence, West, Cameron, Moore, Robert P., Von Hoff, Daniel, Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417372/ https://www.ncbi.nlm.nih.gov/pubmed/34490108 http://dx.doi.org/10.3389/fonc.2021.711043

Ejemplares similares

GZ17-6.02 and axitinib interact to kill renal carcinoma cells
por: Booth, Laurence, et al.
Publicado: (2022)

GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells
por: Booth, Laurence, et al.
Publicado: (2022)

GZ17-6.02 kills prostate cancer cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2022)

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling
por: Booth, Laurence, et al.
Publicado: (2020)

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling
por: Booth, Laurence, et al.
Publicado: (2021)

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
por: Booth, Laurence, et al.
Publicado: (2021)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016)

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

The +Gz recovery of consciousness curve
por: Whinnery, Typ, et al.
Publicado: (2014)

GZ7 and GZ8 – Two Zircon Reference Materials for SIMS U‐Pb Geochronology
por: Nasdala, Lutz, et al.
Publicado: (2018)

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
por: Martinez-Marti, A, et al.
Publicado: (2017)

The +Gz-induced loss of consciousness curve
por: Whinnery, Typ, et al.
Publicado: (2013)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
por: Gerber, David E., et al.
Publicado: (2022)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
por: La Monica, Silvia, et al.
Publicado: (2019)

Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface
por: Belluomini, L., et al.
Publicado: (2021)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Completion of R602
por: CERN. Geneva. ISR Experiments Committee
Publicado: (1973)

Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
por: Li, Xin, et al.
Publicado: (2014)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
por: Bukhari, Ali A., et al.
Publicado: (2013)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Aurora A activation in mitosis promoted by BuGZ
por: Huang, Yuejia, et al.
Publicado: (2018)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
por: Booth, Laurence, et al.
Publicado: (2016)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours
por: Yue-Yun, Chen, et al.
Publicado: (2019)

Who is who in R602
por: Baum, L, et al.
Publicado: (1973)

Poster Sessions 602-806
Publicado: (2004)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vipg219hfcdlj6b5k0boaljovn